NPPA To Appoint Agency For Providing Data And Information On Pharmaceutical Products

Mumbai : The National Pharmaceutical Pricing Authority (NPPA) will soon appoint agency for providing data and information on pharmaceutical products.

The agency is envisaged to provide data and information on pharmaceutical products in the country overall, and also to provide segment, company, region and state-wise data, and the likes. For this purpose, the national drug price regulator has invited agencies and companies having capacity and proven track record of providing similar data and information.

The agency shall primarily be required to provide data as follows on a specific need basis, data on availability and price may be sought from the agency from time to time. Data on availability (overall/State-wise/city-wise) on specific formulation(s) and/or therapeutic group(s) may be asked for.

Data sought will be on pack-wise monthly data of sales units, mat units, monthly sales value, mat sales value units consisting classification (Scheduled/Non Scheduled/Para 19/New drug), Sub group, Brand Name, SKU, Brand & Sub- Group launch date, Therapy, Company Name, Strength and Marketing Company Name, Pack Size, Doses Form, Drug Type, NLEM 15, NLEM 11, GST Rate, Ceiling Price, S.O. Date & S.O. No., MRP, PTR, PTS, % Market Share etc.

It also includes pack-wise monthly data of pharma products consisting of SKU Name, brand and company name, company address classification (Scheduled/ Non- scheduled/Para 19/New drug), Sales Quantity, MRP, PTR & PTS (excluding GST), ceiling price, retail price of new drugs, % market share, GST Rate and marketing company name etc.

Non-scheduled price violation report pack-wise monthly data of pharma products regarding price violation in context of para 20; consisting of SKU Name, brand & company name, company address, sales quantity, MRP and marketing company name etc.

Pack-wise monthly data of pharma products consisting of SKU Name, brand & company name, company address, sales quantity, MRP, PTR & PTS (excluding GST), ceiling price, retail price of new drugs, % market share, GST Rate and marketing company name etc.

The agency should be able to provide the services as per the “Scope of Work”. Each agency shall submit Bids for the work under- Technical Bid, Financial Bid. Additional value added data/information/reports as proposed by the agency that can be submitted on monthly/quarterly/yearly basis. The above should be based on the total financial impact of the annual contract for the work, including taxes.

For the purpose, the NPPA has now issued an online notice inviting tender (NIT) from prospective agencies.This NIT is in supersession of the NIT published on August 19, 2020.

As per the notice, interested agencies or companies who meet the eligibility criteria, may furnishtheir bids against this NIT, along with all the necessary documents and the covering letter, tender acceptance letter, signed and stamped by an authorized signatory online at https://eprocure.gov.in/eprocure/app on or before December 18, 2020 by 4 PM. Manual bids shall not be accepted.

The bids are to be submitted online only. Bids submitted by fax or e-mail, etc. shall not be considered. No further correspondence on the subject will be entertained.

Tender Document may be downloaded from Central Public Procurement Portal (CPPP) site https://eprocure.gov.in/eprocure/app.

Companies have been asked to submit their bids against a NIT for providing data and information on pharmaceutical products. The eligible companies should have the capacity and proven track record of providing data and information as per the prescribed scope of work of NPPA.

Submission of bids in response to this NIT shall be deemed to have been done after careful study and examination with full understanding of its terms, conditions and implications.

Related Posts

TN, Karnataka, Rajasthan declare highest number of NSQs in January

New Delhi:  Around 29% of the total Not of Standard Quality (NSQ) drug samples reported by the State drug testing laboratories in the month of January were collected and tested…

Centre reorganises CDSCO Zone Baddi amid Drug Quality Concerns

Baddi:  Amid rising concerns over drug quality and repeated regulatory red flags, the Centre has moved to tighten oversight in Baddi—one of India’s largest pharmaceutical manufacturing hubs—by restructuring the Central…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

TN, Karnataka, Rajasthan declare highest number of NSQs in January

TN, Karnataka, Rajasthan declare highest number of NSQs in January

Centre reorganises CDSCO Zone Baddi amid Drug Quality Concerns

Centre reorganises CDSCO Zone Baddi amid Drug Quality Concerns

CDSCO modifies norms for testing permissions to speed up drug approvals

CDSCO modifies norms for testing permissions to speed up drug approvals

British men jailed for smuggling cocaine into Bali

British men jailed for smuggling cocaine into Bali

Andhra milk adulteration: Four dead, seven in critical condition

Andhra milk adulteration: Four dead, seven in critical condition

Allahabad HC rejects bail pleas of two accused in Phensedyl syrup case

Allahabad HC rejects bail pleas of two accused in Phensedyl syrup case